David A. Frank

19.5k citations

170 papers · 13.2k indexed · 4 hit papers · h-index 61

Impact in

Oncology top 0.2%
- Cytokine Signaling Pathways and Interactions
Immunology top 0.5%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology

Papers in

Oncology 102
- Cytokine Signaling Pathways and Interactions 87
- Cancer-related Molecular Pathways 12
Genetics 31
- Chronic Lymphocytic Leukemia Research 27

Co-authors: Jerome Ritz Michael E. Greenberg Sarah R. Walker Sudipta Mahajan Erik A. Nelson James V. Alvarez Azad Bonni Traci E. Battle
Journals: Blood (25 papers)The Journal of Immunology (8 papers)Cancer Research (7 papers)Journal of Biological Chemistry (6 papers)Proceedings of the National Academy of Sciences (6 papers)
Partner nations: United States Canada Sweden

In The Last Decade

David A. Frank

167 papers receiving 13.0k citations

Hit Papers

align trajectories log scale

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors 2013 · 422 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Nature Genetics
2006 Blood
2005 PLoS Medicine
1997 Science

Peers

Countries citing papers authored by David A. Frank

Since Specialization

Citations

This map shows the geographic impact of David A. Frank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Frank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Frank more than expected).

Fields of papers citing papers by David A. Frank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Frank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Frank. The network helps show where David A. Frank may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David A. Frank, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Frank Line = papers co-authored together David A. Frank links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation Cancers ·Weiyuan Wang, Weide Qian, Kilian P. V. Hekhuis, 방경주, David A. Frank	2024	10
2	Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms Clinical Cancer Research ·Mihret Woldemariam, David A. Frank	2024	1
3	The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies Frontiers in Immunology ·Weiyuan Wang, Weide Qian, Christine Kim, 정요람, Yoko Yokoyama, R.G. Schurgers, David A. Frank	2023	35
4	Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Clinical Cancer Research ·Evan C. Chen, Men Ke, Betül KALKAN YILMAZ, Geoffrey Fell, 和彦武, Olga Pozdnyakova, Daniel J. DeAngelo, Ilene Galinsky, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Rebecca Leonard, Bojan Lohak, Zhongguang Wu, Donna Neuberg, A. Thomas Look, Richard M. Stone, David A. Frank, Jacqueline S. Garcia	2022	6
5	Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability Disease Models & Mechanisms ·Li Wang, Matteo Astone, Sk. Kayum Alam, Zhu Zhu, Wuhong Pei, David A. Frank, Shawn M. Burgess, Luke H. Hoeppner	2021	52
6	Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly- l -glutamic Acid–coated Layer-by-Layer Nanoparticles Molecular Cancer Therapeutics ·Betül KALKAN YILMAZ, Lisa N. Heppler, Susana P. Egusquiaguirre, Natalie Boehnke, Santiago Correa, Michael J. Lakey, Prace Ustavu, Sharmistha Pal, Douglas S. Richardson, Alexander R. Ivanov, Daphne A. Haas‐Kogan, Daniel K. Nomura, Paula T. Hammond, David A. Frank	2021	9
7	A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML Blood ·Rūta Sincevičiūtė, Shanisha Gordon, Srinivas Aluri, Yang Shi, D. Sathyamurthy, Gaurav S. Choudhary, Lauren Shapiro, Kith Pradhan, David A. Frank, Sergei B. Koralov, Amit Verma, Aditi Shastri	2021	0
8	Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 Molecular Cancer Therapeutics ·Suhu Liu, Sarah R. Walker, Erik A. Nelson, Ashwin Kumar, Michael Xiang, Patricia A. Toniolo, Jun Qi, Richard M. Stone, Martha Wadleigh, James E. Bradner, David A. Frank	2014	51
9	Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells PLoS ONE ·Ellen Weisberg, Arghya Ray, Erik A. Nelson, Sophia Adamia, Rosemary Barrett, Martin Sattler, Chengsheng Zhang, John Daley, David A. Frank, Edward Fox, James D. Griffin	2011	38
10	Reciprocal Effects of STAT5 and STAT3 in Breast Cancer Molecular Cancer Research ·Sarah R. Walker, Erik A. Nelson, Lihua Zou, A-Hyeon Kim, Sabina Signoretti, Andrea L. Richardson, David A. Frank	2009	107
11	Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor Cancer Research ·James V. Alvarez, Heidi Greulich, William R. Sellers, Matthew Meyerson, David A. Frank	2006	206
12	Monocyte 15-Lipoxygenase Expression Is Regulated by a Novel Cytosolic Signaling Complex with Protein Kinase C δ and Tyrosine-Phosphorylated Stat3 The Journal of Immunology ·Ashis Bhattacharjee, Bo Xu, David A. Frank, Gerald M. Feldman, Martha K. Cathcart	2006	23
13	TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition Human Molecular Genetics ·Steven Stone, Victor Abkevich, Deanna L. Russell, Robyn Riley, Kirsten M. Timms, Thanh V. Tran, Foteini Xanthou, David A. Frank, Srikanth Jammulapati, Chris Neff, Diana Iliev, Richard E. Gress, Gongping He, Georges C. Frech, Ted D. Adams, Mark H. Skolnick, Jerry S. Lanchbury, Alexander Gutin, Steven C. Hunt, Donna Shattuck	2006	119
14	Identification of a Genetic Signature of Activated Signal Transducer and Activator of Transcription 3 in Human Tumors Cancer Research ·James V. Alvarez, Phillip G. Febbo, Sridhar Ramaswamy, Massimo Loda, Andrea L. Richardson, David A. Frank	2005	166
15	Interleukin 6 upregulates myeloid cell leukemia‐1 expression through a STAT3 pathway in cholangiocarcinoma cells† Hepatology ·Hajime Isomoto, Shogo Kobayashi, Nathan W. Werneburg, Steve F. Bronk, Maria Eugenia Guicciardi, David A. Frank, Gregory J. Gores	2005	191
16	Signal Transduction in Cancer Kluwer Academic Publishers eBooks ·David A. Frank	2004	10
17	TEL/PDGFβR fusion protein activates STAT1 and STAT5 Experimental Hematology ·F Cavallin, Sudipta Mahajan, David A. Frank, Brian Druker, D. Gary Gilliland, Martin Carroll	2000	54
18	Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein Molecular and Cellular Biology ·James Turkson, Tammy Bowman, Jalila Adnane, Yi Zhang, Julie Y. Djeu, Madhavi Sekharam, David A. Frank, Lawrence B. Holzman, Jie Wu, Saı̈d M. Sebti, Richard Jove	1999	226
19	The Functional Synergy Between IL-12 and IL-2 Involves p38 Mitogen-Activated Protein Kinase and Is Associated with the Augmentation of STAT Serine Phosphorylation The Journal of Immunology ·Jared Gollob, Doris Doblhofer, Erin A. Murphy, Jerome Ritz, David A. Frank	1999	126
20	Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential The Yale Journal of Biology and Medicine ·David A. Frank	1983	12

About David A. Frank

David A. Frank is a scholar working on Oncology, Genetics, Immunology, Hematology and Pathology and Forensic Medicine, having authored 170 papers that have together received 13.2k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (87 papers), Chronic Lymphocytic Leukemia Research (27 papers), Immune Cell Function and Interaction (20 papers), Cancer Mechanisms and Therapy (19 papers), Chronic Myeloid Leukemia Treatments (18 papers), PI3K/AKT/mTOR signaling in cancer (13 papers), Cancer-related Molecular Pathways (12 papers) and Acute Myeloid Leukemia Research (11 papers). The work is most often cited by research in Oncology (5.5k citations), Immunology (3.5k citations), Genetics (1.4k citations), Hematology (1.4k citations) and Cancer Research (1.8k citations). David A. Frank has collaborated with scholars based in United States, Canada and Sweden. Frequent co-authors include Jerome Ritz, Michael E. Greenberg, Sarah R. Walker, Sudipta Mahajan, Erik A. Nelson, James V. Alvarez, Azad Bonni, Traci E. Battle, Nadia Carlesso and Matthew Meyerson. Their work appears in journals such as Blood, The Journal of Immunology, Cancer Research, Journal of Biological Chemistry and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact